These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 23615756)
1. Characterization of Statin-Associated Myopathy Case Reports in Thailand Using the Health Product Vigilance Center Database. Boonmuang P; Nathisuwan S; Chaiyakunapruk N; Suwankesawong W; Pokhagul P; Teerawattanapong N; Supsongserm P Drug Saf; 2013 Sep; 36(9):779-87. PubMed ID: 23615756 [TBL] [Abstract][Full Text] [Related]
2. Statin-associated immune-mediated necrotizing myopathy: a retrospective analysis of individual case safety reports from VigiBase. Essers D; Schäublin M; Kullak-Ublick GA; Weiler S Eur J Clin Pharmacol; 2019 Mar; 75(3):409-416. PubMed ID: 30430215 [TBL] [Abstract][Full Text] [Related]
3. Statins and immune-mediated necrotizing myopathy: Variability in the risk. Trenque T; Hadjoudj J; Trenque A; Tralongo F; Martin S; Azzouz B Therapie; 2024; 79(3):365-370. PubMed ID: 37625939 [TBL] [Abstract][Full Text] [Related]
4. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Chatzizisis YS; Koskinas KC; Misirli G; Vaklavas C; Hatzitolios A; Giannoglou GD Drug Saf; 2010 Mar; 33(3):171-87. PubMed ID: 20158283 [TBL] [Abstract][Full Text] [Related]
5. Statin-associated psychiatric adverse events: a case/non-case evaluation of an Italian database of spontaneous adverse drug reaction reporting. Tuccori M; Lapi F; Testi A; Coli D; Moretti U; Vannacci A; Motola D; Salvo F; Rivolta AL; Blandizzi C; Mugelli A; Del Tacca M Drug Saf; 2008; 31(12):1115-23. PubMed ID: 19026028 [TBL] [Abstract][Full Text] [Related]
6. Adherence to drug label recommendations for avoiding drug interactions causing statin-induced myopathy--a nationwide register study. Settergren J; Eiermann B; Mannheimer B PLoS One; 2013; 8(8):e69545. PubMed ID: 23940522 [TBL] [Abstract][Full Text] [Related]
7. Rhabdomyolysis and statins: A pharmacovigilance comparative study between statins. Montastruc JL Br J Clin Pharmacol; 2023 Aug; 89(8):2636-2638. PubMed ID: 37186323 [TBL] [Abstract][Full Text] [Related]
8. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Chang JT; Staffa JA; Parks M; Green L Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925 [TBL] [Abstract][Full Text] [Related]
9. Statins and erectile dysfunction: results of a case/non-case study using the French Pharmacovigilance System Database. Do C; Huyghe E; Lapeyre-Mestre M; Montastruc JL; Bagheri H Drug Saf; 2009; 32(7):591-7. PubMed ID: 19530745 [TBL] [Abstract][Full Text] [Related]
10. Muscle rupture associated with statin use. Ekhart C; de Jong L; Gross-Martirosyan L; van Hunsel F Br J Clin Pharmacol; 2016 Aug; 82(2):473-7. PubMed ID: 27074553 [TBL] [Abstract][Full Text] [Related]
11. Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase. Edwards IR; Star K; Kiuru A Drug Saf; 2007; 30(6):515-25. PubMed ID: 17536877 [TBL] [Abstract][Full Text] [Related]
13. Statin safety: a systematic review. Law M; Rudnicka AR Am J Cardiol; 2006 Apr; 97(8A):52C-60C. PubMed ID: 16581329 [TBL] [Abstract][Full Text] [Related]
14. A systematic review of the drug-drug interaction between statins and colchicine: Patient characteristics, etiologies, and clinical management strategies. Schwier NC; Cornelio CK; Boylan PM Pharmacotherapy; 2022 Apr; 42(4):320-333. PubMed ID: 35175631 [TBL] [Abstract][Full Text] [Related]
15. Safety of herbal products in Thailand: an analysis of reports in the thai health product vigilance center database from 2000 to 2008. Saokaew S; Suwankesawong W; Permsuwan U; Chaiyakunapruk N Drug Saf; 2011 Apr; 34(4):339-50. PubMed ID: 21417506 [TBL] [Abstract][Full Text] [Related]
16. Statin safety: an assessment using an administrative claims database. Cziraky MJ; Willey VJ; McKenney JM; Kamat SA; Fisher MD; Guyton JR; Jacobson TA; Davidson MH Am J Cardiol; 2006 Apr; 97(8A):61C-68C. PubMed ID: 16581331 [TBL] [Abstract][Full Text] [Related]
17. Statin-associated ocular disorders: the FDA and ADRAC data. Mizranita V; Pratisto EH Int J Clin Pharm; 2015 Oct; 37(5):844-50. PubMed ID: 25939673 [TBL] [Abstract][Full Text] [Related]
18. Statin adverse effects: patients' experiences and laboratory monitoring of muscle and liver injuries. Chaipichit N; Krska J; Pratipanawatr T; Jarernsiripornkul N Int J Clin Pharm; 2015 Apr; 37(2):355-64. PubMed ID: 25630895 [TBL] [Abstract][Full Text] [Related]
19. Renin angiotensin system blockers-associated angioedema in the Thai population: analysis from Thai National Pharmacovigilance Database. Win TS; Chaiyakunapruk N; Suwankesawong W; Dilokthornsakul P; Nathisuwan S Asian Pac J Allergy Immunol; 2015 Sep; 33(3):227-35. PubMed ID: 26342120 [TBL] [Abstract][Full Text] [Related]
20. Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991-2006. Molokhia M; McKeigue P; Curcin V; Majeed A PLoS One; 2008 Jun; 3(6):e2522. PubMed ID: 18575628 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]